Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility

Clinical Stage Adult Stem Cell Company Expands Portfolio of
Clinical Indications

PHOENIX–(BUSINESS WIRE)–Creative Medical Technologies, Inc. (CMT) announced today the signing of
a license agreement with LA BioMed granting exclusive rights for United
States patent application #14/508763, covering the use of stem cells for
treatment of male infertility. In the patent application and a
subsequent publication,1 Ronald S. Swerdloff, M.D., an LA
BioMed lead researcher and UCLA professor of medicine, demonstrated that
the administration of bone marrow cells into the testicles of mice with
chemically induced damage to sperm producing cells led to the generation
of new sperm-producing cells. In order to specifically demonstrate that
the cells that were produced originated from the donor bone marrow, the
team used genetically engineered mice possessing Green Fluorescent
Protein (GFP) in every cell of their body. Interestingly, mice that did
not have GFP possessed sperm-producing cells that were green after they
had received intra-testicular administration of GFP bone marrow.

“We are extremely excited about the potential utilization of simple,
autologous (from the same patient) bone marrow stem cells for the
treatment of a condition that possesses a devastating social and
economic toll on members of our society who are affected by it,” said
Timothy Warbington, Chief Executive Officer of Creative Medical
Technologies. “The investment bank Harris Williams reports that
infertility represents a $3 to $4 billion dollar a year market,
currently comprised of fertility drugs and assisted reproductive
technologies.2 While infertility affects 15% of couples,
according to a publication authored by the Cleveland Clinic, male
infertility accounts for 30 to 40% of cases.”3

Subsequent to filing the patent and the original publication, numerous
international scientific groups have reproduced the finding that bone
marrow derived stem cells are capable of giving rise to sperm generating
cells.4,5,6,7.

Thomas Ichim, Ph.D., President of Creative Medical Technologies, stated:
“The broadest claim of this patent provides the potential for an
incredible intellectual property fence surrounding the field of male
reproductive failure and stem cells.”

The patent claim says: “A method of treating infertility and/or
testosterone deficiency in a male mammal, said method comprising:
implanting stem cells into the testes of said mammal whereby said stem
cells differentiate into germ cells and/or Sertoli cells and/or Leydig
cells thereby reducing infertility and/or testosterone deficiency
.”

Creative Medical Technologies plans to accelerate clinical development
of the patent application by leveraging its clinical expertise in the
area of autologous bone marrow cell therapies, in part gained from its
ongoing clinical trial utilizing this approach for treatment of erectile
dysfunction, which is covered in its patent #8,372,797.

“This agreement with CMT is the latest in LA BioMed’s ongoing work to
transform today’s research into tomorrow’s cures,” said David Meyer,
Ph.D., LA BioMed President and CEO. “We are very pleased to be working
with CMT and other companies to bring new therapies, medical devices and
healthcare solutions to patients around the world.”

About LA BioMed

Founded in 1952, LA BioMed is one of the country’s leading nonprofit
independent biomedical research institutes. It has approximately 100
principal researchers conducting studies into improved treatments and
therapies for cancer, inherited diseases, infectious diseases, illnesses
caused by environmental factors and more. LA BioMed is academically
affiliated with the David Geffen School of Medicine at UCLA and located
on the campus of Harbor-UCLA Medical Center. For more information,
please visit www.LABioMed.org.

About Creative Medical Technologies, Inc.

Creative Medical Technologies, Inc. (CMT) and its affiliate Creative
Medical Health, Inc. (CMH) are clinical stage biotechnology companies
specializing in cutting edge stem cell technology in the areas of
urology, cardiovascular disease, orthopedics and type 2 diabetes. In
addition to their work with LA BioMed, CMH and CMT have ongoing
relationships with several leading academic institutions and key opinion
leaders on stem cell technology in the U.S. and abroad.

1 Lue et al. Am J Pathol. 2007 Mar; 170(3): 899–908. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1864883/
2
https://laprensafl.files.wordpress.com/2016/02/fertility_industry_overview_-_2015.05.19_v10.pdf
3
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424520/
4
Tamadon et al. Int J Stem Cells. 2015 Nov;8(2):134-45. http://www.ncbi.nlm.nih.gov/pubmed/26634062
5
Zhang et al. Int J Mol Sci. 2014 Jul 24;15(8):13151-65. http://www.ncbi.nlm.nih.gov/pubmed/25062349
6
Aghamir et al. Urology. 2014 Jul;84(1):82-6. http://www.ncbi.nlm.nih.gov/pubmed/24797037
7
Drusenheimer et al. Soc Reprod Fertil Suppl. 2007;63:69-76. http://www.ncbi.nlm.nih.gov/pubmed/17566262

Contacts

LA BioMed
Laura Mecoy, 310-546-5860
Lmecoy@LABioMed.org
or
Creative
Medical Technologies, Inc.
Creative Medical Health, Inc.
Timothy
Warbington, 602-680-7439
CEO
ceo@creativemedicalhealth.com